Numerai’s Neuropace NPCE Stock Holding History

Numerai’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$312K	Sell	23,725 -5,547	-19%	-$83.2K	0.03%	640
2025 Q4	$452K	Buy	+29,272	New	+$391K	0.05%	422

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Numerai's NPCE Position: Q1 2026 in Review

Numerai reduced its Neuropace (NPCE) stake by 19% in Q1 2026, selling an estimated $83.2K and leaving 23,725 shares worth $312K. The position accounts for 0.03% of the portfolio, ranked #640.

Numerai first reported a position in NPCE in Q4 2025 and has held it in 2 quarters since. The position peaked at $452K in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

Numerai held 23,725 shares of Neuropace worth $312K as of Q1 2026.
Numerai sold 5,547 Neuropace shares in Q1 2026, an estimated $83.2K.
Neuropace made up 0.03% of Numerai's portfolio in Q1 2026, its #640 holding.
Numerai first reported a position in Neuropace in Q4 2025 and has held it in 2 quarters since.
Numerai's Neuropace position peaked at $452K in Q4 2025.
113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Numerai's 13F filing for Q1 2026, filed 15 May 2026.